Sanofi and BioNTech A.G. have entered into a multiyear exclusive collaboration and license agreement to discover and develop as many as five cancer immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).   BioNTech will receive $60 million in upfront and near-term milestone payments, and is eligible to receive more than $300 million in development, regulatory and commercial milestones per product, as well as royalties on sales. Also, BioNTech has the option to co-dev...